Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.0006
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 191842692000.0
- FreeCF/Share 6.7321
- PFCF 11.259
- PE 11.0915
- Debt/Assets 0.3027
- DivYield 0.0414
- ROE 0.3816
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Investor Alert: Robbins LLP Informs Stockholders of the Merck & Co., Inc. Class Action
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 14, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025. Merck is a global healthcare company.
Read More
Lost Money on Merck & Co., Inc. (MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=129379&wire=1 or contact Joseph E. Levi, Esq.
Read More
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=129358&wire=1 or contact Joseph E. Levi, Esq.
Read More
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Published: February 12, 2025 by: TechCrunch
Sentiment: Positive
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools.
Read More
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Merck & Co. Inc. (NYSE: MRK) resulting from allegations that Merck may have issued materially misleading business information to the investing public. So What: If you purchased Merck securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Merck & Co., Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Merck & Co., Inc. (“Merck” or the “Company”) (NYSE: MRK) between February 3, 2022 to February 3, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Michael Cronin v.
Read More
Jim Cramer Says These 2 Large Cap Dividend Stocks Are Hot February Buys
Published: February 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Media personality Jim Cramer often makes bold statements about companies and a lot of times, he proves himself correct.
Read More
Merck: 4 No-Brainer Reasons to Buy This Dip
Published: February 10, 2025 by: MarketBeat
Sentiment: Neutral
Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss expectations or forecasts.
Read More
Better High-Yield Dividend Stock: Pfizer vs. Merck
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert M. Davis J.D.
- Employees 73000